AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03996733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UltrasoundImaging
Description: Participants will exercise the proper visualisation of the right jugular vein at T6 level with USG guidance on a human subject.
Study NCT03996733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UltrasoundImaging
Description: Participants will exercise the proper visualisation of the right jugular vein at T6 level with USG guidance on a human subject.
Study NCT03996733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ModelTraining
Description: Participants will exercise the proper punction of juguler vein with USG guidance on the homemade jugular venous catheterization training model.~Training model will include carotid artery, trachea and plaure in accordance with the real anatomy.
Study NCT02184481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Study NCT02184481 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo training
Study NCT03209661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette
Description: E-Cigarette containing 5.4% nicotine will be administered to determine the effects on vascular function.
Study NCT03209661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine 0%
Description: E-Cigarette containing 0% nicotine will be administered to determine the effects on vascular function.
Study NCT03482167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niagen®
Description: 250 mg capsules (4 capsules daily)
Study NCT03482167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01230892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: 10 mg PO qday
Study NCT01230892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: 100 mg PO qday
Study NCT02695940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 124249 ointment 30 mg/g
Study NCT03209661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Menthol Inhalant Product
Description: Menthol inhaler will be administered to determine the effects on vascular function.
Study NCT02695940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LEO 124249 ointment vehicle
Study NCT00759434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery - Saphenofemoral ligation, saphenous strip and avulsions
Description: Patients undergo Saphenofemoral ligation, inversion stripping of the Long Saphenous Vein and avulsion of varicosities if necessary under a general anaesthetic.
Study NCT00759434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVLT
Description: Patients undergo endovenous laser treatment, using a 810nm laser aiming to occlude the incompetent long saphenous vein from the saphenofemoral junction to the knee. This may then be followed by ambulatory phlebectomy as appropriate. All procedures are to be performed under a local anaesthetic.
Study NCT01321281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AquaCal
Description: AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).
Study NCT01321281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AquaPT
Description: AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.
Study NCT02505152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic intrahepatic portosystemic shunt
Description: Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.
Study NCT02447926 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Leukapheresis
Description: Catheter placement will occur for about 1 hour. The research nurse will schedule leukapheresis on the next day following catheter placement.~On the day of leukapheresis, a blood draw will monitor blood counts, kidney function, liver function, and blood clotting ability. Vital signs will be checked three times over the course of intervention.~During the procedure, blood is mixed with anticoagulant and separated (i.e. red blood cells, white blood cells, platelets, and plasma). 1-1.5 cups of white blood cells will be collected. Leukapheresis will last 3-6 hours.~Remaining components, except for 100-200 ml of plasma, are returned through the catheter. Two teaspoons of blood will be drawn to determine when catheter removal can occur. This part of intervention lasts about 2.5-4 hours.
Study NCT00706992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-MART-1 vaccine
Description: Given subcutaneously
Study NCT01253408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.
Study NCT01253408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will match study drug; taken orally with water twice per day for two days.
Study NCT01086761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye.
Study NCT00080470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bion
Description: battery powered microstimulator
Study NCT00080470 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: bion
Description: battery powered microstimulator
Study NCT03147560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin IPV+ bOPV+ bOPV
Description: Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
Study NCT03147560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin IPV + Sabin IPV + bOPV
Description: Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
Study NCT00706992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1:26-35(27L) peptide vaccine
Description: Given subcutaneously
Study NCT03147560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin IPV + Sabin IPV + Sabin IPV
Description: Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
Study NCT02940925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug: Taxol,cisplatin and capecitabine
Description: Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
Study NCT02940925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Cisplatin and 5-Fluorouracil
Description: Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
Study NCT03375099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lethal Means Counseling
Description: Single session motivational interviewing based interaction aimed to increase the safe storage of firearms in an effort to reduce suicide risk.
Study NCT03375099 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lethal Means Counseling
Description: Single session motivational interviewing based interaction aimed to increase the safe storage of firearms in an effort to reduce suicide risk.
Study NCT03375099 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Stress Reduction
Description: Single session motivational interviewing based interaction aimed to reduce vulnerability to negative outcomes across four domains: sleep, diet, exercise, and stress.
Study NCT04138238 — intervention group
Intervention type: DEVICE
Intervention: Supraflex Cruz Sirolimus-eluting Stent
Description: Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care
Study NCT03498144 — intervention group
Intervention type: DEVICE
Intervention: Anterior segment OCT
Description: lower punctum examination by AS-OCT
Study NCT02849431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: A version of mindfulness-based cognitive therapy that has been adapted for people with a diagnosis of borderline personality disorder. This comprises eight weekly session, each lasting ninety minutes.
Study NCT02928874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EAH (low ED vs. high ED snacks)
Study NCT02120911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab
Description: Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.
Study NCT02080650 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mesenchymal-marker based ferrofluid (c-MET)
Study NCT02080650 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Epithelial cell adhesion molecule (EpCAM) ferrofluid
Study NCT00706992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given subcutaneously
Study NCT00706992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Description: Given intravenously (IV)
Study NCT00838916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: albiglutide weekly injection
Study NCT00838916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: insulin glargine
Study NCT00632541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 200mg po daily
Study NCT00632541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5mg/kg every other week~1 Cycle = 4 weeks
Study NCT00632541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: Imaging every third cycle
Study NCT03361878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Single dose of 500mg oral metformin
Study NCT02136784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: morphine sulfate
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study NCT02136784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydrocodone
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study NCT01922284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA
Description: 8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
Study NCT01922284 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DNA
Description: 8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
Study NCT01922284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-C
Description: 1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
Study NCT01922284 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-C
Description: 1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
Study NCT01922284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CN54rgp140
Description: 100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
Study NCT01922284 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54rgp140
Description: 100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
Study NCT01922284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-AF
Description: 5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
Study NCT01922284 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GLA-AF
Description: 5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
Study NCT04199208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation and Immunonutrition
Description: See study synopsis
Study NCT04199208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Arm
Description: Standard care as per the daily routines of the Hospital at which the study takes place
Study NCT00617318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate
Description: All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks.
Study NCT00617318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks.
Study NCT02780765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heated humidifier
Description: 30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using Heated Humidifier(HH)
Study NCT02780765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mist humidifier
Description: 30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using mist humidifier
Study NCT00171314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
Study NCT00171314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablets 2.5 mg/day/taken orally for 5 years.
Study NCT00650091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Description: Participants will receive 600 mg of NAC three times a day.
Study NCT00650091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo each day.
Study NCT03810209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: adding magnesium sulphate to local anaesthetic in SAP Block
Study NCT03810209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: adding normal saline to local anaesthetic in SAP block
Study NCT02136784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydromorphone HCI
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study NCT02909569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB039110
Description: All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
Study NCT01010711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Migra 3
Description: powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements
Study NCT02136784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxycodone
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study NCT02136784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: buprenorphine
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study NCT02136784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral tablet placebo
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study NCT01205451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A
Study NCT03739476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 milligrams capsule
Description: Compare the incidence of postoperative delirium.
Study NCT03739476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Compare the incidence of postoperative delirium.
Study NCT03347604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Supine spirometry, MIPs and MEPs
Description: We are going to test spirometry while in supine position , and also test respiratory muscles by measuring the maximum inspiratory and maximum expiratory efforts made by patients.
Study NCT01032993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: 300 mg of CoQ10 (three 100 mg chewable tablets) 2 times daily for 4 weeks
Study NCT01032993 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (three chewable tablets) 2 times daily for 4 weeks
Study NCT00945802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FST-201 (dexamethasone 0.1%) Otic Suspension
Description: Instill four drops two times a day
Study NCT00945802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin 0.3%, dexamethasone 0.1%
Description: Instill four drops two times a day
Study NCT00994656 — intervention group
Intervention type: DEVICE
Intervention: Masimo multi-wavelength pulse co-oximeter
Description: Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
Study NCT01345097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty
Study NCT01451034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WHYX cancer group
Description: WHYX cancer diagnosed by pathologic report
Study NCT01451034 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: WHYX cancer group
Description: WHYX cancer diagnosed by pathologic report
Study NCT04915924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate 3™ left ventricular assist system (HM3 LVAS)
Description: Advanced heart failure patients will be implanted with the HM3 LVAS
Study NCT01498081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2115
Description: AZD2115 administered via inhalation